9Bio Therapeutics
9Bio Therapeutics is a biotechnology company focused on engineering biological possibilities in oncology. They utilize a computationally-guided structural biology platform that integrates tumor biochemistry to design drugs selectively targeting tumors based on their unique microenvironment signatures, thereby sparing healthy tissues. This approach aims to create safer and more efficacious cancer therapeutics. Their platform enables reduced side-effects, improved efficacy through superior bioavailability, and the development of precision-targeted therapies like antibody-drug conjugates (ADCs) for targets previously considered undruggable. The company has a pipeline of two discovery-stage therapies, including an ADC targeting liver and muscle invasive bladder cancers, and another ADC for head and neck and metastatic breast cancers that rescues a previously failed clinical asset. 9Bio actively seeks collaborations to develop innovative protein-based therapeutics.
9Bio Therapeutics
9Bio Therapeutics is a biotechnology company focused on engineering biological possibilities in oncology. They utilize a computationally-guided structural biology platform that integrates tumor biochemistry to design drugs selectively targeting tumors based on their unique microenvironment signatures, thereby sparing healthy tissues. This approach aims to create safer and more efficacious cancer therapeutics. Their platform enables reduced side-effects, improved efficacy through superior bioavailability, and the development of precision-targeted therapies like antibody-drug conjugates (ADCs) for targets previously considered undruggable. The company has a pipeline of two discovery-stage therapies, including an ADC targeting liver and muscle invasive bladder cancers, and another ADC for head and neck and metastatic breast cancers that rescues a previously failed clinical asset. 9Bio actively seeks collaborations to develop innovative protein-based therapeutics.